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Today we have an incomplete picture of how much the world is spending on health and disease-related research
and development (R&D). As such it is difficult to align, or even begin to coordinate, health R&D investments with
international public health priorities.
Current efforts to track and map global health research investments are complex, resource-intensive, and
caveat-laden. An ideal situation would be for all research funding to be classified using a set of common standards
and definitions. However, the adoption of such a standard by everyone is not a realistic, pragmatic or even
necessary goal.
It is time for new thinking informed by the innovations in automated online translation - e.g. Yahoo's Babel Fish.
We propose a feasibility study to develop a system that can translate and map the diverse research classification
systems into a common standard, allowing the targeting of scarce research investments to where they are needed
most.A need for accurate information on research
resource flows
Our understanding of how much is spent on health and
disease-related research and development (R&D), who is
spending it, on what, and where, is very limited. This
failure to accurately oversee financial flows for health re-
search hinders our ability to make health research
investments effectively address international public
health priorities. This inability is especially critical where
resources and the capacity to undertake research are low
[1].
The Global Forum for Health Research has published
estimates for global spending on health research for the
past ten years based primarily on a biennial science and
technology (S&T) spending survey conducted by the
OECD [2]. However, teasing out what proportion of S&T
investments actually go to health research is not easy,
requires significant assumptions, and the resulting global
numbers cannot be disaggregated by disease or purpose
of the research (e.g., biomedical versus health systems* Correspondence: terryr@who.int
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complex and difficult for strategists and policy makers.
So the existence of comprehensive and accurate infor-
mation on research expenditure across the globe would
bring a range of benefits to individual researchers, fun-
ders, national governments, and to those involved in
managing and directing research resources. Better esti-
mates of R&D resource flows would enable the compari-
son and benchmarking of what is being spent in for
example malaria drug development versus drug delivery
research, or biomedical versus health systems research,
or how much is spent on cancer research in different
countries. It would help research funders to make stra-
tegic investments, enable coordination and reduce dupli-
cation to increase the impact of the billions of dollars
that are invested in health research every year.A kaleidoscope of R & D classification systems
Our current view of the global health research landscape
is further obscured by the diverse classification systems
and nomenclatures that the funders of research have
adopted to define their portfolios and deliver against
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currently in use across the globe. These systems typically
combine a description of the health or disease topic,
often using the International Statistical Classification of
Diseases and Related Health Problems (ICD10) or Med-
ical Subject Headings developed by the US National Li-
brary of Medicine (MeSH), with a description of the
objective, purpose or type of research. While the result-
ing outputs differ markedly the similarity in the ap-
proach to classification - with use of a disease code
combined with a description of the research purpose -
suggests there is a common understanding or principle
of what a classification system should incorporate.
An ideal improvement would be that all research
investments are classified using an agreed set of stan-
dards and definitions. However, encouraging research
funders to harmonize and align their individual classifi-
cation systems to a common standard may be unwieldy,
impractical and perhaps an unrealistic expectation. In
addition, it is no small challenge for many countries to
provide even the most basic data on their R&D resource
flows over time.
For example, in the UK biomedical field, UK research
funders have classified their funding portfolios against
the Health Research Classification System (HRCS) devel-
oped by the UK Clinical Research Collaboration
(UKCRC) [3]. The HRCS was first used in 2005 to clas-
sify the portfolio of a number of major biomedical fund-
ing bodies and allowed some of the first analysis of
research foci across UK organisations; a second wave of
classification was repeated for 2010 resource flows
across the same organisations to compare and to de-
scribe any trends that may have emerged over time.
While there is interest in using the HRCS by other
European research funders [4], undertaking the actual
classification requires considerable manual coding and
in addition the integration of the classification system
with multiple funders’ grants systems is not a simple
process. This requirement for a manual coding step,
common to the use of any classification system, is both
costly and time consuming.
Translation not standardization
Today the revolution in text, data mining and semantic
web analysis presents us with new opportunities to
achieve automated and large scale translation efforts. In-
stead of organizations being required to classify their
investments using a common standard, it should be feas-
ible to develop a system that can translate diverse re-
search funding descriptions to a “lingua franca” that
delivers systematic and comprehensive maps of resource
flows for the first time.
The precedent is there with several recent innovations.
For example Natural Language Processing (NLP)algorithms used by Collexis to search and match related
documents using free text rather than complicated Bool-
ean search terms and translational software systems used
by the French Multi-Terminology Indexer (F-MTI) [5].
Online language translation, such as Google Translate or
Yahoo’s Babel Fish, is improving and will get better with
cloud technology. These innovations suggest that such a
research translation system might be achievable. The use
of translation tools is currently being explored to track
the impact and outcomes of research [6].
G-FINDER has provided a recent practical demonstra-
tion of how a translation approach can work to produce
insight into international research commitments. Sup-
ported by the Bill & Melinda Gates Foundation, the
G-FINDER survey aims to provide “comprehensive data
to help funders and product developers better under-
stand where funding gaps lie and how their investments
fit into the global picture”. It has done so for one area of
health research, that of product R&D for neglected dis-
eases. G-FINDER now covers all major public, private
and philanthropic funders in high-income countries, and
major funders in some middle-income “innovative devel-
oping countries” [7].
The work involved in collating and reconciling the
data provided by all the funders contributing to the G-
FINDER survey is, however, substantial. The G-FINDER
team has developed its own way of mapping existing
classifications of neglected disease R&D against an
agreed, central code frame, but this is currently a largely
manual process.
First steps: exploring the feasibility of a
translation system
Automation of mapping individual classification systems
against a commonly agreed standard using new software
tools would be a major breakthrough innovation. In our
view, a feasibility study is needed to explore whether
such a mapping and translation approach can deliver
more accurate and insightful resource flow mapping for
health and disease-related R&D.
As part of this study, many practical issues must be
resolved including how to build on what is already
strong and familiar across existing classification systems
that are now in use, and how to generate agreement on
the classification standard. In addition, the mechanism
of translation itself and the degree to which it could be
automated will be a key element in the usefulness of the
envisioned translation system. Different options for such
a mechanism should be explored, as well as how it
would be maintained, curated and governed and how
any reporting and analysis would be delivered.
We propose that a number of principles guide the de-
velopment of a translation system to improve its chances
of success. In our view, a translation system should be:
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to evolve over time; equitable i.e. it meets the needs of
all (or most) global users; not burdensome to users that
supply information and/or interface with the system;
and able to generate output that is open and accessible
to all.
The initial resources required to scope and develop a
translation system may be significant. However, longer
term efficiencies that will be gained through our ability
to track global, regional and national investments in
health and disease R&D, coupled with improved coord-
ination and more strategic investments, should far out-
weigh that initial investment.
Our ultimate goal is to develop a translation tool that
is of value to as many stakeholders as possible, and that
is sufficiently detailed to enable its use in resource flow
mapping and strategy and priority setting. The premise
of our paper is that there is a role for automation to im-
prove the efficiency of R&D classification and, as a con-
sequence increase the likelihood of gaining access to
better data. Such efforts will be essential if the desire for
greater harmonization in global health R&D are ever to
be realised [8].
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